Exagen Inc. (XGN) Misses Q4 EPS by 6c, Revenue Beats, Offers Guidance

Exagen Inc. (NASDAQ: XGN) reported Q4 EPS of ($0.83), $0.06 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $8.66 million.

GUIDANCE:

Exagen Inc. sees Q1 2023 revenue of $9.2-9.7 million, versus the consensus of $9.3 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Worried the AI trade has gone too far? Evercore likes these 4 stocks